Released : September 18, 2019 07:00 RNS Number : 6880M MaxCyte, Inc. 18 September 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2019 ¾ Strong commercial execution and financial performance with 21% year-over-year revenue growth ¾ Cell
Released : September 09, 2019 07:00 RNS Number : 5829L MaxCyte, Inc. 09 September 2019 MaxCyte Announces Presentation at ICLE 2019 Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces today that
Released : August 14, 2019 07:00 RNS Number : 9483I MaxCyte, Inc. 14 August 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 14 August 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life
Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced
Released : July 17, 2019 07:00 RNS Number : 7557F MaxCyte, Inc. 17 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Significant CARMA™ programme progress, 80+ partnered programmes licensed and strong financial performance with 21% year over year revenue growth
Released : July 11, 2019 07:00 RNS Number : 1593F MaxCyte, Inc. 11 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Host Capital Markets Day Today Gaithersburg, Maryland - 11 July 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences
Released : July 05, 2019 16:42 RNS Number : 7002E MaxCyte, Inc. 05 July 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Released : July 05, 2019 16:36 RNS Number : 6992E MaxCyte, Inc. 05 July 2019 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the
Released : June 19, 2019 07:00 RNS Number : 7254C MaxCyte, Inc. 19 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") 2018 Annual Report Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that
Released : June 12, 2019 07:00 RNS Number : 8822B MaxCyte, Inc. 12 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Appointment of Joint Corporate Broker Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage, cell-based therapies and life
